Skip to content
Clinical Trials – home
Research site

Privat Doktor Egeszseguegyi Szolgaltato Zrt.

Hungary Visegradi Utca 40, 1132 Budapest, Hungary

  • 10 trials recruiting
  • Hypertension · Hypertriglyceridaemia · Arteriosclerosis
  • Adult patients

About Specializations

Privat Doktor Egeszseguegyi Szolgaltato Zrt. in Budapest, Hungary specialises in clinical trials of conditions such as Hypertension, Hypertriglyceridaemia, Arteriosclerosis, Cardiovascular disorder, and other specialisations. This site conducts important research.

Main research areas of the site

Cardiovascular Diseases

The cardiology department at Privat Doktor Egeszsegugyi Szolgaltato Zrt. conducts a broad portfolio of studies aimed at major cardiovascular diseases including atherosclerotic disease, atrial fibrillation, heart failure, and hypertension, with the goal of testing new therapies and improving patient outcomes.

  • Reducing major adverse cardiovascular events in high‑risk populations
  • Preventing stroke in patients with atrial fibrillation unsuitable for anticoagulation
  • Slowing chronic kidney disease progression in individuals with hypertension
  • Improving survival and hospitalization rates in heart failure with preserved or reduced ejection fraction
  • Targeting elevated lipoprotein(a) and LDL‑C levels
  • Assessing anti‑inflammatory interventions after myocardial infarction

Based in Budapest, the centre has launched 19 trials with five investigators, partnering with academic and industry collaborators to evaluate innovative drugs and combination regimens for cardiovascular risk reduction.

Nutritional and Metabolic Diseases

Research at the site also focuses on nutritional and metabolic disorders, addressing obesity, type 2 diabetes, hyperlipidemia, and severe hypertriglyceridemia, with studies designed to test novel agents that modify metabolic pathways and improve clinical outcomes.

  • Evaluating therapies that lower fasting triglyceride concentrations
  • Testing weight‑loss agents that also improve glycemic control
  • Investigating treatments that reduce lipoprotein(a) and LDL‑C in inherited hypercholesterolemia
  • Exploring combination regimens for hypertension in patients with metabolic syndrome
  • Assessing drugs that prevent acute pancreatitis in severe hypertriglyceridemia

The Budapest facility leverages its multidisciplinary expertise to advance therapeutic options for metabolic disease, contributing to the growing evidence base that links metabolic health with cardiovascular risk.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Visegradi Utca 401132 BudapestHungary
Recruiting now
10 trials
Conditions studied
12

More sites in BudapestHungary

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

18 clinical trials

Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:ZILEBESIRAN
  • Sponsor:Alnylam Pharmaceuticals Inc.
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim Espana S.A.
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Ezetimibe
  • Sponsor:NewAmsterdam Pharma B.V.

Cardiac failure

Recruiting
Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim International GmbH
Countries:HungaryHungary
  • Participants:65+ years
  • Substances:Abelacimab
  • Sponsor:Anthos Therapeutics Inc.
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Azd5004
  • Sponsor:AstraZeneca AB
Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues
  • Sponsor:Arrowhead Pharmaceuticals Inc.
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Bi 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Myocardial infarction

Not recruiting
Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Abcentra LLC
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.